-
1دورية أكاديمية
المؤلفون: Stratigos, Alexander J.1 (AUTHOR) alstrat2@gmail.com, Garbe, Claus2 (AUTHOR), Dessinioti, Clio1 (AUTHOR), Lebbe, Celeste3 (AUTHOR), Bataille, Veronique4 (AUTHOR), Bastholt, Lars5 (AUTHOR), Dreno, Brigitte6 (AUTHOR), Concetta Fargnoli, Maria7 (AUTHOR), Forsea, Ana M.8 (AUTHOR), Frenard, Cecille6 (AUTHOR), Harwood, Catherine A.9 (AUTHOR), Hauschild, Axel10 (AUTHOR), Hoeller, Christoph11 (AUTHOR), Kandolf-Sekulovic, Lidija12 (AUTHOR), Kaufmann, Roland13 (AUTHOR), Kelleners-Smeets, Nicole W.J.14 (AUTHOR), Malvehy, Josep15 (AUTHOR), del Marmol, Veronique16 (AUTHOR), Middleton, Mark R.17 (AUTHOR), Moreno-Ramirez, David18 (AUTHOR)
المصدر: European Journal of Cancer. Mar2020, Vol. 128, p83-102. 20p.
مصطلحات موضوعية: *THERAPEUTIC use of monoclonal antibodies, *CANCER relapse, *CANCER invasiveness, *COMBINED modality therapy, *SURGICAL excision, *HEALTH care teams, *HISTOLOGICAL techniques, *LYMPH node surgery, *MEDICAL protocols, *METASTASIS, *PALLIATIVE treatment, *RADIOTHERAPY, *RISK assessment, *SKIN tumors, *SQUAMOUS cell carcinoma
مصطلحات جغرافية: EUROPE
الشركة/الكيان: UNITED States. Food & Drug Administration
-
2دورية أكاديمية
المؤلفون: Petrella, Teresa M.1 teresa.petrella@sunnybrook.ca, Robert, Caroline2 caroline.robert@gustaveroussy.fr, Richtig, Erika3 erika.richtig@medunigraz.at, Jr.Miller, Wilson H.4 wilsonmiller@gmail.com, Masucci, Giuseppe V.5 giuseppe.masucci@ki.se, Walpole, Euan6 euan.walpole@health.qld.gov.au, Lebbe, Celeste7 celeste.lebbe@aphp.fr, Steven, Neil8 N.M.Steven@bham.ac.uk, Middleton, Mark R.9 mark.middleton@oncology.ox.ac.uk, Hille, Darcy10 darcy_hille@merck.com, Zhou, Wei10 wei.zhou2@merck.com, Ibrahim, Nageatte10 nageatte.ibrahim@merck.com, Cebon, Jonathan11 jonathan.cebon@onjcri.org.au
المصدر: European Journal of Cancer. Nov2017, Vol. 86, p115-124. 10p.
مصطلحات موضوعية: *THERAPEUTIC use of monoclonal antibodies, *QUALITY of life, *HEALTH status indicators, *LONGITUDINAL method, *MELANOMA, *MONOCLONAL antibodies, *HEALTH outcome assessment, *QUESTIONNAIRES, *STATISTICAL sampling, *RANDOMIZED controlled trials, *TREATMENT effectiveness, *IPILIMUMAB, *THERAPEUTICS